• In the past few days, Sunoco LP released its 2026 guidance, projecting adjusted EBITDA of US$3.10–US$3.30 billion, outlining a multi‑year US$500 million‑plus annual bolt‑on acquisition pipeline, and targeting at least 5% annual distribution growth supported by synergies from the Parkland acquisition.
• By pairing higher EBITDA guidance with a clear capital allocation plan and a commitment to continued distributable cash flow growth, Sunoco signaled how the Parkland deal could reshape its scale, funding priorities, and income profile for unitholders.
• We’ll now examine how Sunoco’s higher 2026 EBITDA guidance and acquisition pipeline could influence its existing investment narrative and risk profile.

Rare earth metals are the new gold rush. Find out which 38 stocks are leading the charge.

Sunoco Investment Narrative Recap

To own Sunoco, you need to believe its fuel distribution and midstream model can keep generating solid cash flows despite structural headwinds in gasoline demand and the transition away from petroleum. The new 2026 guidance, with higher adjusted EBITDA and a visible bolt on acquisition pipeline, reinforces the near term growth story but does not remove the key risk around leverage and integration as the Parkland assets and other deals are absorbed.

The most relevant update here is Sunoco’s 2026 guidance, which ties the higher US$3.10–US$3.30 billion adjusted EBITDA outlook directly to Parkland synergies and at least US$500 million per year of acquisitions. For investors focused on distributions, the target of at least 5 percent annual growth backed by this plan sharpens the near term catalyst, while also making execution on M&A and balance sheet discipline even more important.

But while this income growth focus is appealing, investors should be aware of how elevated leverage and acquisition integration risk could...

Sunoco's narrative projects $26.7 billion revenue and $1.6 billion earnings by 2028.

Uncover how Sunoco's forecasts yield a $64.71 fair value, a 12% upside to its current price.

Exploring Other Perspectives

Five fair value estimates from the Simply Wall St Community span from US$32.51 to US$3,444.12, underscoring how far apart individual views can be. Against that wide range, Sunoco’s reliance on acquisitions to support EBITDA and distribution growth highlights why you may want to explore several viewpoints before weighing the partnership’s long term resilience.

Explore 5 other fair value estimates on Sunoco - why the stock might be worth 44% less than the current price!

Build Your Own Sunoco Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Sunoco research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
• Our free Sunoco research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Sunoco's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Our top stock finds are flying under the radar-for now. Get in early:

• Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.
• AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.